Drugs / Keverprazan

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06777732 Mar → Sep 2025 overdue Helicobacter pylori infectious disease Nanjing First Hospital, Nanjing Medical University Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT06760065 Jan 2025 → Dec 2027 expected Helicobacter pylori infectious disease Sixth Affiliated Hospital, Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 42 trials
Phase 4 NCT06412640 Jun → Dec 2024 Helicobacter pylori infectious disease Nanjing First Hospital, Nanjing Medical University Unknown No outcome recorded
Phase 4 NCT07122024 Feb 2024 → Aug 2025 overdue Helicobacter pylori infectious disease Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase not applicable1 trial
NCT06851468 Mar → Nov 2025 Helicobacter pylori infectious disease Key Laboratory for Gastrointestinal Diseases of Gansu Province Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06734260 Comparator Sep 2024 → Nov 2025 overdue Eighth Affiliated Hospital, Sun Yat-sen University Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Keverprazan ClinicalTrials.gov intervention name — accepted as the source's own label NCT07122024
5

NCT06777732

NCT06851468

NCT06760065

NCT06412640

NCT06734260

Known as Keverprazan Hydrochloride Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral” NCT06734260
Action Inhibit “stronger and longer inhibition effect on gastric acid compared with PPIs” NCT06734260
Route Oral “Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oralNCT06734260